ABCG2 and cancer: Other ongoing or completed clinical studies with tariquidar, paclitaxel, docetaxel, carboplatin and cisplatin suggest that therapeutic modulation of the ABC transporter activity might be beneficial for some LC patients in the future [57,58], but the cancer cell specificity of such drugs has to be improved.